Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) price on Wednesday, February 05, rose 3.56% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $4.94.
A look at the stock’s price movement, the close in the last trading session was $4.77, moving within a range at $4.76 and $5.02. The beta value (5-Year monthly) was 0.024. Turning to its 52-week performance, $11.56 and $4.28 were the 52-week high and 52-week low respectively. Overall, MRVI moved -13.03% over the past month.
Maravai LifeSciences Holdings Inc’s market cap currently stands at around $1.25 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 57.79M for the company’s revenue for the quarter, with a low and high estimate of 56.7M and 60.4M respectively. The average forecast suggests down to a -22.06% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 260.53M, representing a -9.83% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that MRVI is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 6 recommend MRVI as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MRVI’s current price about -4.05% and -7.91% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 43.73, while 7-day volatility ratio is 6.28% and 8.95% in the 30-day chart. Further, Maravai LifeSciences Holdings Inc (MRVI) has a beta value of -0.08, and an average true range (ATR) of 0.41. Analysts have given the company’s stock an average 52-week price target of $22, forecast between a low of $10 and high of $25. Looking at the price targets, the low is -102.43% off current price level while to achieve the yearly target high, price needs to move -406.07%. Nonetheless, investors will most likely welcome a -345.34% jump to $22 which is the analysts’ median price.
If we refocus on Maravai LifeSciences Holdings Inc (NASDAQ:MRVI), historical trading data shows that trading volumes averaged 1.99 over the past 10 days and 2.11 million over the past 3 months. The company’s latest data on shares outstanding shows there are 141.59 million shares.
The 16.91% of Maravai LifeSciences Holdings Inc’s shares are in the hands of company insiders while institutional holders own 87.63% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.92 million on 2025-01-15, giving us a short ratio of 4.9. The data shows that as of 2025-01-15 short interest in Maravai LifeSciences Holdings Inc (MRVI) stood at 750.0 of shares outstanding, with shares short rising to 8.29 million registered in 2024-12-13. Current price change has pushed the stock -9.36% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MRVI stock continues to rise going into the next quarter.
